01, E. coil: rifampin:294 159, nebacetin:0.2 +/- 0.5 CFU ml(-1), P = 0.001), while only rifampin was toxic against ECs (daptomycin:30.88 +/- 5.44, rifampin:5.13 +/- 5.08, nebacetin:28.50 +/- 3.82 ECs/field, P = 0.0003).
Conclusions: Nebacetin showed excellent in vitro antibacterial activity against both Gram-positive and -negative pathogens representing an effective candidate for vascular graft impregnation.
CX-6258 (C) 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.”
“Introduction. Orally administered angiotensin receptor antagonists administered after bare-metal stent implantation and even after drug-eluting stent implantation seem to lower in-stent restenosis rates. Whether valsartan-eluting stents are similarly effective was tested here in a first-in-man trial.
Materials and methods. The efficacy of a polymer-free drug-eluting stent coated with 300 mcg valsartan was compared to a coating with a 2% rapamycin
solution in small (<= 2.5 mm) coronary vessels with and without oral valsartan on the basis of the YUKON Choice stent system (Translumina GmbH, Hechingen, Germany). Fifteen patients (eight males, Curaxin 137 HCl mean age 64.4 +/- 7.7 years) were treated with YUKON Choice valsartan-eluting stents and 30 patients (24 males, mean age 65.7 +/- 8.4 years) received YUKON Choice rapamycin-eluting stents. Clopidogrel was given for six months in all patients.
Results. Within the first 30 clays, no adverse events occurred in either group. Binary in-stent restenosis rate was 30.8% (four in 13 angiographic controls) in the valsartan-c luting stent group and 35.0% (eight in 20 angiographic controls) in the rapamycin-eluting YUKON Choice stent group. Mean late lumen loss was 0.78 +/- 0.53 mm and 0.79 +/- 0.58 check details mm, respectively. Target lesion and target vessel revascularisation rate was 26.6% and 25.0%, respectively. No restenoses in rapamycin-eluting YUKON Choice stents appeared in 12 patients with adjunct oral valsartan administration.
Conclusions. If polymer-free YUKON Choice
stents are used in small vessels, valsartan-eluting stents show an identical efficacy as rapamycin-loaded stents. In patients with rapamycin eluting YUKON Choice stents it seems that the efficacy can be increased by oral valsartan administration.”
“Some host-adapted bacterial pathogens are capable of causing persistent infections in humans. For example, Helicobacter pylori inhabits the human gastric mucosa and persistence can be lifelong. Salmonella enterica serovar Typhi causes systemic infections that involve colonization of the reticuloendothelial system and some individuals become lifelong carriers. In this review, I compare and contrast the different lifestyles of Helicobacter and Salmonella within the host and the strategies they have evolved to persist in mammalian hosts.